Lupin gets USFDA nod to market generic skin ointment

PTI New Delhi | Updated on January 16, 2018 Published on December 14, 2016


Pharma firm Lupin has received approval from the US health regulator to market its Desoximetasone ointment, used for providing relief from inflammation and itching in a skin disease.

The company has received final approval to market its Desoximetasone ointment USP, 0.05 per cent from the United States Food & Drug Administration (USFDA), Lupin said in a filing to BSE.

The product filing is from the company’s Pithampur manufacturing facility, it added.

The Mumbai-based company’s product is the generic version of Taro Pharms North’s Topicort ointment in the same strength.

According to IMS, MAT September 2016 sales data, Topicort had US sales of $12.1 million, Lupin said.

The ointment is “indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,” it added.

The Lupin stock was trading marginally up at Rs 1,493 in afternoon on the BSE.

Published on December 14, 2016
This article is closed for comments.
Please Email the Editor